Josefa Briceno, MD Medical Head, DDR/ADC Franchise AstraZenca

LYNPARZA in HER2-negative Metastatic Breast Cancer and Germline BRCA Mutations Interview with:

Josefa Briceno, MD Medical Head, DDR/ADC Franchise AstraZenca

Dr. Briceno

Josefa Briceno, MD
Medical Head, DDR/ADC Franchise
AstraZenca What is the background for this study? What are the main findings?

Response: In January 2018, the US FDA expanded the approved use of LYNPARZA to treat patients with HER2- negative metastatic breast cancer with germline BRCA mutations based on positive results from the Phase III OlympiAD trial, which demonstrated the benefit of LYNPARZA over standard of care in physician’s choice chemotherapy in this patient population. LUCY is a Phase IIIb interim analysis aimed to evaluate the clinical effectiveness and safety of LYNPARZA in a real-world setting and has been expanded to include a group of patients with somatic BRCA mutations.

A total of 252 patients with HER2-negative metastatic breast cancer with germline BRCA mutations were enrolled in the open-label, single-arm, Phase IIIb study. Patients received a taxane and/or anthracycline in the (neo)adjuvant/metastatic setting, and ≤2 lines of chemotherapy.

The primary end point of the study was investigator-defined progression-free survival (PFS), and secondary end points included overall survival, time to first subsequent therapy or death, and investigator-assessed clinical response rate. The interim analysis was planned to take place after 160 progression-free survival events.

Overall, treatment lasted for a median of 7.9 months, and the median progression-free survival was 8.1 months (95% confidence interval of 6.9-8.7; 166 progression-free survival events).

In addition, the median time to first subsequent therapy or death was 9.7 months (95% confidence interval of 8.7-11.1) and the investigator-assessed clinical response rate was 48.6% (95% confidence interval of 42.2-55.0).

Adverse events of all grades were reported in >20% of patients were nausea, anemia, asthenia, vomiting, and fatigue. Grade ≥3 adverse events were reported in 24.6% of patients, and 4.4% of patients had an adverse event that led to treatment discontinuation. What should readers take away from your report?

Response: Interim results in this real-world population of patients with HER2-negative metastatic breast cancer with germline BRCA mutations were consistent with the OlympiAD study thereby supporting LYNPARZA as a chemotherapy-free alternative in this treatment setting. We hope these results will help inform and guide clinical practice. What recommendations do you have for future research as a result of this study?

Response: The results from this study are promising and further our understanding of LYNPARZA in patients with HER2-negative (HER2-) metastatic breast cancer and germline BRCA mutations. We have a broad and advanced clinical trial development program geared towards exploring how LYNPARZA may affect PARP-dependent tumors across multiple cancer types. We plan to continue this area of research along with working toward our overall goal of improving outcomes for patients.


ASCO 2020
Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis
Abstract #1087
Poster #172

The information on is provided for educational purposes only, and is in no way intended to diagnose, endorse, cure, endorse or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.



Last Updated on June 2, 2020 by Marie Benz MD FAAD